Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Athira Pharma, Inc.

Athira Pharma, Inc. (ATHA) Stock Overview

Explore Athira Pharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.

ATHA●NASDAQ
HealthcareBiotechnology
$6.75
$0.44(6.12%)
U.S. Market opens in 15h 20m

Athira Pharma, Inc. (ATHA)

Meyka AI Score

Z

Key Financials

Market Cap26.6M
P/E Ratio-0.28
EPS (TTM)$-9.67
ROE-3.81%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$6.05

ATHA Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Athira Pharma, Inc. (NASDAQ: ATHA) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Athira Pharma, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ATHA on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $6.05 for the NASDAQ listing.

Key metrics behind Athira Pharma, Inc.'s NASDAQ-traded stock include a P/E ratio of -0.28 and a market capitalization of 26.6M. Combined with our AI analysis, these give both institutional and retail investors a clear view of ATHA on the NASDAQ.

Price Performance (NASDAQ: ATHA)

1-Day Change
40.92%
5-Day Change
38.89%
1-Month Change
-6.12%
3-Month Change
75.32%
6-Month Change
72.19%
Year-to-Date (YTD) Change
-3.02%
1-Year Change
53.06%
3-Year Change
-80.93%
5-Year Change
-97.30%
All-Time (Max) Change
-96.05%

Contact Information

https://www.athira.com
425 620 8501
18706 North Creek Parkway, Bothell, WA, 98011

Company Facts

260 Employees
IPO DateSep 18, 2020
CountryUS

Frequently Asked Questions